Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT00825721Phase 2Unknown
Phase 2, randomised, single-blind trial of ethylenediaminetetraacetic acid in nuclear cataract (NS) (4 arms), sponsored by Chakshu Research, Inc. Primary endpoint: Best-corrected visual acuity at 360 days. Status: unknown.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT00825721.